▶ 調査レポート

世界の未分化リンパ腫キナーゼALK阻害剤市場 2021:企業別、地域別、種類・用途別

• 英文タイトル:Global Anaplastic Lymphoma Kinase ALK Inhibitor Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

GlobalInfoResearchが調査・発行した産業分析レポートです。世界の未分化リンパ腫キナーゼALK阻害剤市場 2021:企業別、地域別、種類・用途別 / Global Anaplastic Lymphoma Kinase ALK Inhibitor Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026 / GIR-202A2450資料のイメージです。• レポートコード:GIR-202A2450
• 出版社/出版日:GlobalInfoResearch / 2021年12月
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、100ページ
• 納品方法:Eメール(納期:2~3日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥522,000 (USD3,480)▷ お問い合わせ
  Multi User¥783,000 (USD5,220)▷ お問い合わせ
  Corporate User¥1,044,000 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査資料では、未分化リンパ腫キナーゼALK阻害剤のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。未分化リンパ腫キナーゼALK阻害剤の種類別市場規模(第1世代ALK阻害剤、第2世代ALK阻害剤、第3世代ALK阻害剤)、用途別市場規模(病院薬局、小売薬局、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・未分化リンパ腫キナーゼALK阻害剤の市場概要
・企業情報(企業概要、製品概要、販売量、価格、売上):Astellas Pharma、AstraZeneca、Betta Pharmaceuticals、GlaxoSmithKline、Merck、Novartis、Pfizer、Roche、Takeda Pharmaceuticals、Turning Point Therapeutics
・企業別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年:第1世代ALK阻害剤、第2世代ALK阻害剤、第3世代ALK阻害剤
・用途別分析2016年-2026年:病院薬局、小売薬局、その他
・未分化リンパ腫キナーゼALK阻害剤の北米市場規模2016年-2026年:アメリカ、カナダ、メキシコ
・未分化リンパ腫キナーゼALK阻害剤のヨーロッパ市場規模2016年-2026年:ドイツ、イギリス、フランス、ロシア、イタリア
・未分化リンパ腫キナーゼALK阻害剤のアジア市場規模2016年-2026年:中国、日本、韓国、インド、東南アジア、オーストラリア
・未分化リンパ腫キナーゼALK阻害剤の南米市場規模2016年-2026年:ブラジル、アルゼンチン
・未分化リンパ腫キナーゼALK阻害剤の中東・アフリカ市場規模2016年-2026年:サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Anaplastic Lymphoma Kinase ALK Inhibitor market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Anaplastic Lymphoma Kinase ALK Inhibitor size is estimated to be million in 2021 from USD million in 2020, with a change of % between 2020 and 2021. The global Anaplastic Lymphoma Kinase ALK Inhibitor market size is expected to grow at a CAGR of % for the next five years.

Market segmentation
Anaplastic Lymphoma Kinase ALK Inhibitor market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
First Generation ALK Inhibitor
Second Generation ALK Inhibitor
Third Generation ALK Inhibitor

Market segment by Application can be divided into
Hospital Pharmacy
Retail Pharmacy
Others

The key market players for global Anaplastic Lymphoma Kinase ALK Inhibitor market are listed below:
Astellas Pharma
AstraZeneca
Betta Pharmaceuticals
GlaxoSmithKline
Merck
Novartis
Pfizer
Roche
Takeda Pharmaceuticals
Turning Point Therapeutics

Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Anaplastic Lymphoma Kinase ALK Inhibitor product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Anaplastic Lymphoma Kinase ALK Inhibitor, with price, sales, revenue and global market share of Anaplastic Lymphoma Kinase ALK Inhibitor from 2019 to 2021.
Chapter 3, the Anaplastic Lymphoma Kinase ALK Inhibitor competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Anaplastic Lymphoma Kinase ALK Inhibitor breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Anaplastic Lymphoma Kinase ALK Inhibitor market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Anaplastic Lymphoma Kinase ALK Inhibitor sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

1 Market Overview
1.1 Anaplastic Lymphoma Kinase ALK Inhibitor Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 First Generation ALK Inhibitor
1.2.3 Second Generation ALK Inhibitor
1.2.4 Third Generation ALK Inhibitor
1.3 Market Analysis by Application
1.3.1 Overview: Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size & Forecast
1.4.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales in Value (2016-2026))
1.4.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales in Volume (2016-2026)
1.4.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Price by Type (2016-2026) & (US$/Unit)
1.5 Global Anaplastic Lymphoma Kinase ALK Inhibitor Production Capacity Analysis
1.5.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Total Production Capacity (2016-2026)
1.5.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Anaplastic Lymphoma Kinase ALK Inhibitor Market Drivers
1.6.2 Anaplastic Lymphoma Kinase ALK Inhibitor Market Restraints
1.6.3 Anaplastic Lymphoma Kinase ALK Inhibitor Trends Analysis
2 Manufacturers Profiles
2.1 Astellas Pharma
2.1.1 Astellas Pharma Details
2.1.2 Astellas Pharma Major Business
2.1.3 Astellas Pharma Anaplastic Lymphoma Kinase ALK Inhibitor Product and Services
2.1.4 Astellas Pharma Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Anaplastic Lymphoma Kinase ALK Inhibitor Product and Services
2.2.4 AstraZeneca Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Betta Pharmaceuticals
2.3.1 Betta Pharmaceuticals Details
2.3.2 Betta Pharmaceuticals Major Business
2.3.3 Betta Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Product and Services
2.3.4 Betta Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 GlaxoSmithKline
2.4.1 GlaxoSmithKline Details
2.4.2 GlaxoSmithKline Major Business
2.4.3 GlaxoSmithKline Anaplastic Lymphoma Kinase ALK Inhibitor Product and Services
2.4.4 GlaxoSmithKline Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Merck
2.5.1 Merck Details
2.5.2 Merck Major Business
2.5.3 Merck Anaplastic Lymphoma Kinase ALK Inhibitor Product and Services
2.5.4 Merck Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business
2.6.3 Novartis Anaplastic Lymphoma Kinase ALK Inhibitor Product and Services
2.6.4 Novartis Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Anaplastic Lymphoma Kinase ALK Inhibitor Product and Services
2.7.4 Pfizer Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Roche
2.8.1 Roche Details
2.8.2 Roche Major Business
2.8.3 Roche Anaplastic Lymphoma Kinase ALK Inhibitor Product and Services
2.8.4 Roche Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 Takeda Pharmaceuticals
2.9.1 Takeda Pharmaceuticals Details
2.9.2 Takeda Pharmaceuticals Major Business
2.9.3 Takeda Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Product and Services
2.9.4 Takeda Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.10 Turning Point Therapeutics
2.10.1 Turning Point Therapeutics Details
2.10.2 Turning Point Therapeutics Major Business
2.10.3 Turning Point Therapeutics Anaplastic Lymphoma Kinase ALK Inhibitor Product and Services
2.10.4 Turning Point Therapeutics Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Manufacturer
3.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Anaplastic Lymphoma Kinase ALK Inhibitor
3.4 Market Concentration Rate
3.4.1 Top 3 Anaplastic Lymphoma Kinase ALK Inhibitor Manufacturer Market Share
3.4.2 Top 6 Anaplastic Lymphoma Kinase ALK Inhibitor Manufacturer Market Share
3.5 Global Anaplastic Lymphoma Kinase ALK Inhibitor Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Anaplastic Lymphoma Kinase ALK Inhibitor Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size by Region
4.1.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales in Volume by Region (2016-2026)
4.1.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Region (2016-2026)
4.2 North America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue (2016-2026)
4.3 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Revenue (2016-2026)
4.4 Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Revenue (2016-2026)
4.5 South America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue (2016-2026)
4.6 Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales in Volume by Type (2016-2026)
5.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Type (2016-2026)
5.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales in Volume by Application (2016-2026)
6.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Application (2016-2026)
6.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2016-2026)
7.2 North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2016-2026)
7.3 North America Anaplastic Lymphoma Kinase ALK Inhibitor Market Size by Country
7.3.1 North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales in Volume by Country (2016-2026)
7.3.2 North America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2016-2026)
8.2 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2016-2026)
8.3 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Market Size by Country
8.3.1 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales in Volume by Country (2016-2026)
8.3.2 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2016-2026)
9.2 Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2016-2026)
9.3 Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Market Size by Region
9.3.1 Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2016-2026)
10.2 South America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2016-2026)
10.3 South America Anaplastic Lymphoma Kinase ALK Inhibitor Market Size by Country
10.3.1 South America Anaplastic Lymphoma Kinase ALK Inhibitor Sales in Volume by Country (2016-2026)
10.3.2 South America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2016-2026)
11.2 Middle East & Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2016-2026)
11.3 Middle East & Africa Anaplastic Lymphoma Kinase ALK Inhibitor Market Size by Country
11.3.1 Middle East & Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Anaplastic Lymphoma Kinase ALK Inhibitor Typical Distributors
12.3 Anaplastic Lymphoma Kinase ALK Inhibitor Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

List of Tables
Table 1. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Type, (USD Million), 2021-2026
Table 2. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Application, (USD Million), 2021-2026
Table 3. Astellas Pharma Basic Information, Manufacturing Base and Competitors
Table 4. Astellas Pharma Major Business
Table 5. Astellas Pharma Anaplastic Lymphoma Kinase ALK Inhibitor Product and Services
Table 6. Astellas Pharma Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 8. AstraZeneca Major Business
Table 9. AstraZeneca Anaplastic Lymphoma Kinase ALK Inhibitor Product and Services
Table 10. AstraZeneca Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Betta Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 12. Betta Pharmaceuticals Major Business
Table 13. Betta Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Product and Services
Table 14. Betta Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 16. GlaxoSmithKline Major Business
Table 17. GlaxoSmithKline Anaplastic Lymphoma Kinase ALK Inhibitor Product and Services
Table 18. GlaxoSmithKline Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Merck Basic Information, Manufacturing Base and Competitors
Table 20. Merck Major Business
Table 21. Merck Anaplastic Lymphoma Kinase ALK Inhibitor Product and Services
Table 22. Merck Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Novartis Basic Information, Manufacturing Base and Competitors
Table 24. Novartis Major Business
Table 25. Novartis Anaplastic Lymphoma Kinase ALK Inhibitor Product and Services
Table 26. Novartis Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Pfizer Basic Information, Manufacturing Base and Competitors
Table 28. Pfizer Major Business
Table 29. Pfizer Anaplastic Lymphoma Kinase ALK Inhibitor Product and Services
Table 30. Pfizer Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Roche Basic Information, Manufacturing Base and Competitors
Table 32. Roche Major Business
Table 33. Roche Anaplastic Lymphoma Kinase ALK Inhibitor Product and Services
Table 34. Roche Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Takeda Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 36. Takeda Pharmaceuticals Major Business
Table 37. Takeda Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Product and Services
Table 38. Takeda Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Turning Point Therapeutics Basic Information, Manufacturing Base and Competitors
Table 40. Turning Point Therapeutics Major Business
Table 41. Turning Point Therapeutics Anaplastic Lymphoma Kinase ALK Inhibitor Product and Services
Table 42. Turning Point Therapeutics Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Manufacturer (2019-2021e) & (K Units)
Table 44. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 45. Market Position of Manufacturers in Anaplastic Lymphoma Kinase ALK Inhibitor, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 46. Global Anaplastic Lymphoma Kinase ALK Inhibitor Production Capacity by Company, (K Units): 2020 VS 2021
Table 47. Head Office and Anaplastic Lymphoma Kinase ALK Inhibitor Production Site of Key Manufacturer
Table 48. Anaplastic Lymphoma Kinase ALK Inhibitor New Entrant and Capacity Expansion Plans
Table 49. Anaplastic Lymphoma Kinase ALK Inhibitor Mergers & Acquisitions in the Past Five Years
Table 50. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Region (2016-2021e) & (K Units)
Table 51. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Region (2021-2026) & (K Units)
Table 52. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Region (2016-2021e) & (USD Million)
Table 53. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Region (2021-2026) & (USD Million)
Table 54. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2016-2021e) & (K Units)
Table 55. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2021-2026) & (K Units)
Table 56. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Type (2016-2021e) & (USD Million)
Table 57. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Type (2021-2026) & (USD Million)
Table 58. Global Anaplastic Lymphoma Kinase ALK Inhibitor Price by Type (2016-2021e) & (US$/Unit)
Table 59. Global Anaplastic Lymphoma Kinase ALK Inhibitor Price by Type (2021-2026) & (US$/Unit)
Table 60. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2016-2021e) & (K Units)
Table 61. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2021-2026) & (K Units)
Table 62. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Application (2016-2021e) & (USD Million)
Table 63. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Application (2021-2026) & (USD Million)
Table 64. Global Anaplastic Lymphoma Kinase ALK Inhibitor Price by Application (2016-2021e) & (US$/Unit)
Table 65. Global Anaplastic Lymphoma Kinase ALK Inhibitor Price by Application (2021-2026) & (US$/Unit)
Table 66. North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2016-2021e) & (K Units)
Table 67. North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2021-2026) & (K Units)
Table 68. North America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2016-2021e) & (USD Million)
Table 69. North America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2021-2026) & (USD Million)
Table 70. North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2016-2021e) & (K Units)
Table 71. North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2021-2026) & (K Units)
Table 72. North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2016-2021e) & (K Units)
Table 73. North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2021-2026) & (K Units)
Table 74. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2016-2021e) & (K Units)
Table 75. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2021-2026) & (K Units)
Table 76. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2016-2021e) & (USD Million)
Table 77. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2021-2026) & (USD Million)
Table 78. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2016-2021e) & (K Units)
Table 79. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2021-2026) & (K Units)
Table 80. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2016-2021e) & (K Units)
Table 81. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2021-2026) & (K Units)
Table 82. Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Region (2016-2021e) & (K Units)
Table 83. Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Region (2021-2026) & (K Units)
Table 84. Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Region (2016-2021e) & (USD Million)
Table 85. Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Region (2021-2026) & (USD Million)
Table 86. Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2016-2021e) & (K Units)
Table 87. Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2021-2026) & (K Units)
Table 88. Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2016-2021e) & (K Units)
Table 89. Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2021-2026) & (K Units)
Table 90. South America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2016-2021e) & (K Units)
Table 91. South America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2021-2026) & (K Units)
Table 92. South America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2016-2021e) & (USD Million)
Table 93. South America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2021-2026) & (USD Million)
Table 94. South America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2016-2021e) & (K Units)
Table 95. South America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2021-2026) & (K Units)
Table 96. South America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2016-2021e) & (K Units)
Table 97. South America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2021-2026) & (K Units)
Table 98. Middle East & Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2016-2021e) & (K Units)
Table 99. Middle East & Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2021-2026) & (K Units)
Table 100. Middle East & Africa Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2016-2021e) & (USD Million)
Table 101. Middle East & Africa Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2021-2026) & (USD Million)
Table 102. Middle East & Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2016-2021e) & (K Units)
Table 103. Middle East & Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2021-2026) & (K Units)
Table 104. Middle East & Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2016-2021e) & (K Units)
Table 105. Middle East & Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2021-2026) & (K Units)
Table 106. Direct Channel Pros & Cons
Table 107. Indirect Channel Pros & Cons
Table 108. Anaplastic Lymphoma Kinase ALK Inhibitor Typical Distributors
Table 109. Anaplastic Lymphoma Kinase ALK Inhibitor Typical Customers
List of Figures
Figure 1. Anaplastic Lymphoma Kinase ALK Inhibitor Picture
Figure 2. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Type in 2020
Figure 3. First Generation ALK Inhibitor
Figure 4. Second Generation ALK Inhibitor
Figure 5. Third Generation ALK Inhibitor
Figure 6. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Application in 2020
Figure 7. Hospital Pharmacy
Figure 8. Retail Pharmacy
Figure 9. Others
Figure 10. Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 11. Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size and Forecast (2016-2026) & (USD Million)
Figure 12. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales (2016-2026) & (K Units)
Figure 13. Global Anaplastic Lymphoma Kinase ALK Inhibitor Price by Type (2016-2026) & (US$/Unit)
Figure 14. Global Anaplastic Lymphoma Kinase ALK Inhibitor Production Capacity (2016-2026) & (K Units)
Figure 15. Global Anaplastic Lymphoma Kinase ALK Inhibitor Production Capacity by Geographic Region: 2020 VS 2021
Figure 16. Anaplastic Lymphoma Kinase ALK Inhibitor Market Drivers
Figure 17. Anaplastic Lymphoma Kinase ALK Inhibitor Market Restraints
Figure 18. Anaplastic Lymphoma Kinase ALK Inhibitor Market Trends
Figure 19. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Manufacturer in 2020
Figure 20. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Manufacturer in 2020
Figure 21. Anaplastic Lymphoma Kinase ALK Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 22. Top 3 Anaplastic Lymphoma Kinase ALK Inhibitor Manufacturer (Revenue) Market Share in 2020
Figure 23. Top 6 Anaplastic Lymphoma Kinase ALK Inhibitor Manufacturer (Revenue) Market Share in 2020
Figure 24. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Region (2016-2026)
Figure 25. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Region (2016-2026)
Figure 26. North America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue (2016-2026) & (USD Million)
Figure 27. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Revenue (2016-2026) & (USD Million)
Figure 28. Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Revenue (2016-2026) & (USD Million)
Figure 29. South America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue (2016-2026) & (USD Million)
Figure 30. Middle East & Africa Anaplastic Lymphoma Kinase ALK Inhibitor Revenue (2016-2026) & (USD Million)
Figure 31. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Type (2016-2026)
Figure 32. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Type (2016-2026)
Figure 33. Global Anaplastic Lymphoma Kinase ALK Inhibitor Price by Type (2016-2026) & (US$/Unit)
Figure 34. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Application (2016-2026)
Figure 35. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Application (2016-2026)
Figure 36. Global Anaplastic Lymphoma Kinase ALK Inhibitor Price by Application (2016-2026) & (US$/Unit)
Figure 37. North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Type (2016-2026)
Figure 38. North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Application (2016-2026)
Figure 39. North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Country (2016-2026)
Figure 40. North America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Country (2016-2026)
Figure 41. United States Anaplastic Lymphoma Kinase ALK Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. Canada Anaplastic Lymphoma Kinase ALK Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Mexico Anaplastic Lymphoma Kinase ALK Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Type (2016-2026)
Figure 45. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Application (2016-2026)
Figure 46. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Country (2016-2026)
Figure 47. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Country (2016-2026)
Figure 48. Germany Anaplastic Lymphoma Kinase ALK Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. France Anaplastic Lymphoma Kinase ALK Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. United Kingdom Anaplastic Lymphoma Kinase ALK Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Russia Anaplastic Lymphoma Kinase ALK Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Italy Anaplastic Lymphoma Kinase ALK Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Region (2016-2026)
Figure 54. Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Application (2016-2026)
Figure 55. Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Region (2016-2026)
Figure 56. Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Region (2016-2026)
Figure 57. China Anaplastic Lymphoma Kinase ALK Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Japan Anaplastic Lymphoma Kinase ALK Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Korea Anaplastic Lymphoma Kinase ALK Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. India Anaplastic Lymphoma Kinase ALK Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Southeast Asia Anaplastic Lymphoma Kinase ALK Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Australia Anaplastic Lymphoma Kinase ALK Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. South America Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Type (2016-2026)
Figure 64. South America Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Application (2016-2026)
Figure 65. South America Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Country (2016-2026)
Figure 66. South America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Country (2016-2026)
Figure 67. Brazil Anaplastic Lymphoma Kinase ALK Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Argentina Anaplastic Lymphoma Kinase ALK Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Middle East & Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Type (2016-2026)
Figure 70. Middle East & Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Application (2016-2026)
Figure 71. Middle East & Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Country (2016-2026)
Figure 72. Middle East & Africa Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Country (2016-2026)
Figure 73. Turkey Anaplastic Lymphoma Kinase ALK Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Egypt Anaplastic Lymphoma Kinase ALK Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Saudi Arabia Anaplastic Lymphoma Kinase ALK Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. South Africa Anaplastic Lymphoma Kinase ALK Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Sales Channel: Direct Channel vs Indirect Channel
Figure 78. Methodology
Figure 79. Research Process and Data Source